INTELLIA THERAPEUTICS, INC. Operating Income
INTELLIA THERAPEUTICS, INC. (NTLA) reported Operating Income of -$112.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$112.76M.
- INTELLIA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$100.53M.
- INTELLIA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$98.71M.
- INTELLIA THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$111.48M.
- INTELLIA THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$440.99M.
- INTELLIA THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$534.26M.
- INTELLIA THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$515.29M.
- INTELLIA THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$458.16M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 8 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$112.76M 10-Q · filed 2026-08-06 | -$213.29M 10-Q · filed 2026-08-06 | -$312.00M derived: sum of 3 quarters · filed 2026-08-06 | -$423.48M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$100.53M 10-Q · filed 2026-05-11 | -$199.24M derived: sum of 2 quarters · filed 2026-05-11 | -$310.72M derived: sum of 3 quarters · filed 2026-05-11 | -$420.71M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$98.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$210.19M derived: sum of 2 quarters · filed 2026-02-26 | -$320.18M derived: sum of 3 quarters · filed 2026-08-06 | -$440.99M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$111.48M 10-Q · filed 2025-11-06 | -$221.47M derived: sum of 2 quarters · filed 2026-08-06 | -$342.28M 10-Q · filed 2025-11-06 | -$478.73M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$110.00M 10-Q · filed 2026-08-06 | -$230.80M 10-Q · filed 2026-08-06 | -$367.25M derived: sum of 3 quarters · filed 2026-08-06 | -$512.02M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$120.81M 10-Q · filed 2026-05-11 | -$257.25M derived: sum of 2 quarters · filed 2026-05-11 | -$402.02M derived: sum of 3 quarters · filed 2026-05-11 | -$541.07M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$136.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$281.22M derived: sum of 2 quarters · filed 2026-02-26 | -$420.26M derived: sum of 3 quarters · filed 2026-02-26 | -$534.26M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$144.77M 10-Q · filed 2025-11-06 | -$283.81M derived: sum of 2 quarters · filed 2025-11-06 | -$397.82M 10-Q · filed 2025-11-06 | -$537.71M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$139.04M 10-Q · filed 2025-08-07 | -$253.05M 10-Q · filed 2025-08-07 | -$392.94M derived: sum of 3 quarters · filed 2026-02-26 | -$524.04M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$114.00M 10-Q · filed 2025-05-08 | -$253.90M derived: sum of 2 quarters · filed 2026-02-26 | -$385.00M derived: sum of 3 quarters · filed 2026-02-26 | -$517.34M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$139.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$271.00M derived: sum of 2 quarters · filed 2026-02-26 | -$403.33M derived: sum of 3 quarters · filed 2026-02-26 | -$515.29M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$131.11M 10-Q · filed 2024-11-07 | -$263.44M derived: sum of 2 quarters · filed 2024-11-07 | -$375.40M 10-Q · filed 2024-11-07 | -$485.49M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$132.33M 10-Q · filed 2024-08-08 | -$244.29M 10-Q · filed 2024-08-08 | -$354.38M derived: sum of 3 quarters · filed 2025-02-27 | -$459.91M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$111.96M 10-Q · filed 2024-05-09 | -$222.04M derived: sum of 2 quarters · filed 2025-02-27 | -$327.57M derived: sum of 3 quarters · filed 2025-02-27 | -$425.88M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | -$110.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$215.62M derived: sum of 2 quarters · filed 2025-02-27 | -$313.92M derived: sum of 3 quarters · filed 2025-02-27 | -$458.16M 10-K · filed 2025-02-27 | |
| 2022-09-30 | -$105.53M 10-Q · filed 2023-11-09 | -$203.83M derived: sum of 2 quarters · filed 2023-11-09 | -$348.08M 10-Q · filed 2023-11-09 | -$428.49M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | -$98.30M 10-Q · filed 2023-08-03 | -$242.55M 10-Q · filed 2023-08-03 | -$322.96M derived: sum of 3 quarters · filed 2024-02-22 | -$394.95M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | -$144.25M 10-Q · filed 2023-05-04 | -$224.66M derived: sum of 2 quarters · filed 2024-02-22 | -$296.65M derived: sum of 3 quarters · filed 2024-02-22 | -$365.67M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | -$80.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$152.41M derived: sum of 2 quarters · filed 2024-02-22 | -$221.43M derived: sum of 3 quarters · filed 2024-02-22 | -$267.85M 10-K · filed 2024-02-22 | |
| 2021-09-30 | -$71.99M 10-Q · filed 2022-11-03 | -$141.01M derived: sum of 2 quarters · filed 2022-11-03 | -$187.44M 10-Q · filed 2022-11-03 | -$229.83M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$69.02M 10-Q · filed 2022-08-04 | -$115.44M 10-Q · filed 2022-08-04 | -$157.84M derived: sum of 3 quarters · filed 2022-08-04 | -$185.94M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$46.42M 10-Q · filed 2022-05-05 | -$88.82M derived: sum of 2 quarters · filed 2022-05-05 | -$116.93M derived: sum of 3 quarters · filed 2022-05-05 | -$149.96M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | -$42.40M 10-K · filed 2021-02-26 | -$70.50M derived: sum of 2 quarters · filed 2021-11-04 | -$103.53M derived: sum of 3 quarters · filed 2021-11-04 | -$136.58M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$28.10M 10-Q · filed 2021-11-04 | -$61.14M derived: sum of 2 quarters · filed 2021-11-04 | -$94.18M 10-Q · filed 2021-11-04 | -$123.95M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$33.03M 10-Q · filed 2021-08-05 | -$66.08M 10-Q · filed 2021-08-05 | -$95.85M derived: sum of 3 quarters · filed 2021-08-05 | -$121.18M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$33.05M 10-Q · filed 2021-05-06 | -$62.82M derived: sum of 2 quarters · filed 2021-05-06 | -$88.15M derived: sum of 3 quarters · filed 2021-05-06 | -$115.61M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | -$29.77M 10-K · filed 2021-02-26 | -$55.10M derived: sum of 2 quarters · filed 2021-02-26 | -$82.56M derived: sum of 3 quarters · filed 2021-02-26 | -$106.37M 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$25.33M 10-K · filed 2021-02-26 | -$52.79M derived: sum of 2 quarters · filed 2021-02-26 | -$76.60M 10-Q · filed 2020-11-05 | -$97.34M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-06-30 | -$27.46M 10-K · filed 2021-02-26 | -$51.27M 10-Q · filed 2020-08-06 | -$72.02M derived: sum of 3 quarters · filed 2021-02-26 | -$96.11M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-03-31 | -$23.81M 10-K · filed 2021-02-26 | -$44.55M derived: sum of 2 quarters · filed 2021-02-26 | -$68.65M derived: sum of 3 quarters · filed 2021-02-26 | -$92.25M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | -$20.75M 10-K · filed 2020-02-27 | -$44.84M derived: sum of 2 quarters · filed 2020-02-27 | -$68.44M derived: sum of 3 quarters · filed 2020-02-27 | -$90.87M 10-K · filed 2021-02-26 | |
| 2018-09-30 | -$24.10M 10-K · filed 2020-02-27 | -$47.69M derived: sum of 2 quarters · filed 2020-02-27 | -$70.12M 10-Q · filed 2019-10-31 | -$94.84M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | -$23.59M 10-K · filed 2020-02-27 | -$46.02M 10-Q · filed 2019-08-01 | -$70.74M derived: sum of 3 quarters · filed 2020-02-27 | -$86.61M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | -$22.43M 10-K · filed 2020-02-27 | -$47.15M derived: sum of 2 quarters · filed 2020-02-27 | -$63.02M derived: sum of 3 quarters · filed 2020-02-27 | -$79.04M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | -$24.71M 10-K · filed 2019-02-27 | -$40.59M derived: sum of 2 quarters · filed 2019-02-27 | -$56.61M derived: sum of 3 quarters · filed 2019-02-27 | -$69.56M 10-K · filed 2020-02-27 | |
| 2017-09-30 | -$15.88M 10-K · filed 2019-02-27 | -$31.89M derived: sum of 2 quarters · filed 2019-02-27 | -$44.84M 10-Q · filed 2018-10-31 | -$55.66M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | -$16.02M 10-K · filed 2019-02-27 | -$28.96M 10-Q · filed 2018-08-01 | -$39.79M derived: sum of 3 quarters · filed 2019-02-27 | -$47.48M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | -$12.95M 10-K · filed 2019-02-27 | -$23.77M derived: sum of 2 quarters · filed 2019-02-27 | -$31.47M derived: sum of 3 quarters · filed 2019-02-27 | -$38.41M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | -$10.82M 10-K · filed 2018-03-14 | -$18.52M derived: sum of 2 quarters · filed 2018-03-14 | -$25.46M derived: sum of 3 quarters · filed 2018-03-14 | -$32.16M 10-K · filed 2019-02-27 | |
| 2016-09-30 | -$7.70M 10-K · filed 2018-03-14 | -$14.64M derived: sum of 2 quarters · filed 2018-03-14 | -$21.34M 10-Q · filed 2017-10-31 | -$26.83M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-06-30 | -$6.95M 10-K · filed 2018-03-14 | -$13.64M 10-Q · filed 2017-08-01 | -$19.13M derived: sum of 3 quarters · filed 2018-03-14 | -$22.43M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-03-31 | -$6.69M 10-K · filed 2018-03-14 | -$12.19M derived: sum of 2 quarters · filed 2018-03-14 | -$15.49M derived: sum of 3 quarters · filed 2018-03-14 | -$18.91M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2015-12-31 | -$5.49M 10-K · filed 2017-03-14 | -$8.79M derived: sum of 2 quarters · filed 2017-03-14 | -$12.21M derived: sum of 3 quarters · filed 2017-03-14 | -$13.41M 10-K · filed 2018-03-14 | |
| 2015-09-30 | -$3.30M 10-K · filed 2017-03-14 | -$6.72M derived: sum of 2 quarters · filed 2017-03-14 | -$7.92M 10-Q · filed 2016-11-01 | ||
| 2015-06-30 | -$3.42M 10-K · filed 2017-03-14 | -$4.62M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$1.20M 10-K · filed 2017-03-14 | ||||
| 2014-12-31 | -$9.54M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |